Navigation Links
Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
Date:9/19/2007

Study Showed That NICOM can be Used to Accurately Measure Cardiac Output

During Cardiopulmonary Exercise Testing (CPX)

WASHINGTON, September 19 /PRNewswire/ -- Cheetah Medical Inc., developers of the Cheetah NICOM(TM) system, for non-invasive, real-time cardiac output monitoring, announced at HFSA the results of the study "Markers of ventilatory inefficiency in heart failure are related to peak exercise."

The study, led by Dr. Jon Myers of Stanford University and the VA Palo Alto Health Care System, used the NICOM to measure the cardiac output of 36 patients. Results showed that the NICOM accurately measured cardiac output. This is the first time that the NICOM was used in a study during cardiopulmonary exercise on heart failure patients.

Dr. Myers concluded, "NICOM provided accurate measurements of cardiac output and thoracic fluid during cardiopulmonary exercise. The possibility of using a non-invasive, accurate tool to measure cardiac output may provide clinicians with an important diagnostic tool that can contribute to optimization of CHF treatment and provide an early indication of disease escalation."

The NICOM(TM) Cardiac Output Monitor, developed by Cheetah Medical, is a portable system that utilizes the proprietary BIOREACTANCE(TM) technology to measure cardiac output in virtually any clinical setting. Cheetah considers BIOREACTANCE to be a superior modality to measure cardiac output, especially in clinical settings where continuous monitoring of cardiac output is imperative, and in clinical environments such as intensive care units, emergency departments and during stress tests, where there is significant electrical noise and patient movement.

Cheetah's BIOREACTANCE(TM) technology has been validated in the United States and Europe on hundreds of hemodynamically challenged patients in a variety of clinical settings, in the presence of significant environmental factors.

Laura Rector, General Manager of Cheetah Medical in the United States stated, "This study is important because, until the NICOM System, there has not been a technology as practical and simple, that is available to clinicians to accurately and easily provide exercise cardiac output. The NICOM System is a robust diagnostic tool for measuring cardiac output. The patented BIOREACTANCE technology opens opportunities for clinicians to improve patient care based on real-time accurate cardiac output measurements."

Ms. Rector continued, "We have now established our US Sales and Marketing Organization and we are excited about starting sales in the US Market. Based on the initial market reaction, there is clearly a great, untapped need for Cheetah's unique and proprietary technology."

About the BIOREACTANCE(TM) Technology

The Cheetah family of NICOM Cardiac Output Monitors implements the unique and proprietary BIOREACTANCE(TM) technology. BIOREACTANCE is a novel technology platform which analyzes changes in amplitude as well as frequency of electrical impulses as they traverse the chest. These changes are analyzed by software programming to provide a continuous, highly accurate and stable, non-invasive measurement of cardiac output and other cardiac parameters.

About the Company

Cheetah Medical is based in Tel Aviv, Israel and Indianapolis, Indiana. The company is establishing NICOM(TM) as a frontline tool to monitor cardiac function in inpatient and outpatient areas of high unmet need. Importantly, this unique and proprietary technology has been proven to provide accurate and reliable measurements of cardiac output, even during patient movement and across a variety of body types. These features enable the device to be used in several important clinical applications, including intensive care, anesthesia and peri-operative settings, step down, emergency room, dialysis clinic, cardiac care unit, ECO(TM) (Exercise CO testing), CRT-pacemaker optimization, thoracic fluid content (TFC) for acute and chronic heart failure management, home Holter monitoring of cardiac rhythm, thoracic fluid content and cardiac function together, and out-patient heart failure diagnosis/ monitoring.

For more information please visit http://www.cheetah-medical.com or e-mail, cheetah@cheetah-medical.com.

Contact: Laura Rector

+1-317-603-1822


'/>"/>
SOURCE Cheetah Medical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GE Medicals Technologies Aid Battle Against Cancer
2. GE Medicals Acquisitions May Prompt More Purchases
3. DGGE Analysis for Non-Invasive Studies of Primate Diet
4. Radiology advance points way to non-invasive brain-cancer treatment
5. Criticare gets OK to market portable cardiac monitor
6. Versatile Reporter Vectors for Monitoring Viral Transduction
7. Cis-Reporting System Monitors Intracellular Calcium Mobilization
8. Cis-Reporting System Monitors Intracellular Calcium Mobilization
9. Monitoring transfection efficiency by green fluorescent protein (GFP) detection with the Agilent 2100 bioanalyzer
10. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
11. Monitoring Bacterial Genetic Diversity in a Freshwater Lake Using TTGE and DNA Sequence Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , ... February 09, 2016 , ... The American ... organization’s history, it is offering its 2016 AAT Member Certification Qualification Course for Technicians ... curriculum for the webinar, which will include a detailed review of hardware, software, and ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... 2016 --> ... innovation-driven oncology company developing next generation cancer therapeutics ... announced that chairman emeritus of Tata Sons Limited, ... company as part of the first close of ... Navam Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ...
Breaking Biology Technology:
(Date:1/21/2016)... PUNE, India , January 21, 2016 /PRNewswire/ ... According to a new market research report "Emotion ... Learning, and Others), Software Tools (Facial Expression, Voice ... and Regions - Global forecast to 2020", published ... Market is expected to reach USD 22.65 Billion ...
(Date:1/15/2016)... SAN JUAN, Puerto Rico , Jan. 15, 2016 ... forcing companies big and small to find new ways ... data driven culture. iOS and ... their device based on biometrics, transforming it into a ... can request that users swipe their fingerprint on their ...
(Date:1/8/2016)... United Kingdom , Jan. 8, 2016   Bruin ... products, today announced the closing of a $9 million financing. ... from the financing will be used to accelerate the commercialization ... detecting early-stage pressure ulcers. United Kingdom ... CE Mark approval. The device,s introduction has been met with ...
Breaking Biology News(10 mins):